Life Extension Magazine

Life Extension Magazine 2013

Report

Protect Against Destructive Migraines

By Stephen Grant

Protect Against Destructive Migraines

Each day, 14 million people experience the paralyzing pain of migraines.1 Every 10 seconds someone is admitted to an emergency room with a migraine-related condition.1

As painful and debilitating as migraines can be, scientists never believed they caused any long-term damage.

But they were wrong.

Scientists have recently uncovered an alarming discovery: Migraines cause lasting brain damage that is closely related to the changes seen in seizures, strokes, and dementia.2,3 Indeed, having a history of migraines is turning out to be a risk factor for some of the most-feared chronic brain disorders.2,4-6

Current migraine treatments include drugs originally developed for treating epilepsy.7-9 Although these drugs are effective in the short term, they were never meant for long-term use, they are fraught with side effects, and they fail to address the underlying cause.7,9

As scientists searched for treatment alternatives to anti-epileptic drugs, they uncovered two ingredients that provide a therapeutic dual-action against the changes in the brain that lead to migraines.

By restoring chemical balance to the brain and improving brain blood flow, gastrodin and magnesium target the underlying mechanisms behind crippling migraine pain, providing safe and effective relief for crippling migraine pain.10-14

Getting to the Root of Migraine Pain

Brain imaging studies show that people with migraines have visible abnormalities that are similar to those seen in stroke victims and in people with dementia.15,16 And some large-scale epidemiological studies suggest that people with chronic migraines are at increased risk for strokes and dementia.17,18

An abrupt reduction in brain blood flow occurs during an ischemic stroke, and more gradually in the condition known as vascular dementia.19,20 Similarly, before and during a migraine attack, blood flow in specific brain regions begins to drop.21-23 In all three cases—stroke, vascular dementia, and migraines—the result is increased vulnerability of brain cells to dysfunction, degeneration, and eventually death.19-23

But brain blood flow disturbances are just part of the picture in migraine headaches. In addition to (and perhaps as a result of) those disruptions, people with migraines show a harmful imbalance in the brain’s excitatory and inhibitory chemical activity.4,24,25

The Migraine/Seizure Connection

Normally, your brain maintains a healthy balance between excitatory and inhibitory activity by modulating neurotransmitters such as GABA.

When you do not have enough GABA, you can end up with the uncoordinated electrical “storm” that presents itself as an epileptic seizure. We now know that a milder version of this process occurs during a migraine.3,26

Because the imbalance between excitatory and inhibitory neurotransmitters is common to both migraines and to seizures, anti-epileptic drugs might appear to be a promising treatment option for migraine sufferers. Such drugs generally elevate the GABA-related activity in the brain, which has a calming, inhibitory effect.8,9 They also reduce concentrations of excitatory neurotransmitters, further restoring a normal balance.

The problem is that seizure drugs are loaded with adverse effects and were never meant to be used on a long-term basis for the prevention of something like a migraine.7,9 In fact, the US Food and Drug Administration has issued a warning that all anti-epileptic drugs are associated with increased risk of suicidal ideation and behavior.7

Fortunately, magnesium formulations and gastrodin work to improve cerebral blood flow and restore neurotransmitter input as do anti-epileptic drugs…but with a much better safety profile.11-13,27-32 The result is a natural treatment that has been proven to reduce the number and severity of migraine attacks.30

Reduce the Number and Duration of Migraine Attacks

Reduce the Number and Duration of Migraine Attacks  

Gastrodin, originally extracted from the root of the orchid Gastrodia elata, has been used for centuries in traditional Chinese medicine, especially for disorders involving the central nervous system such as headaches and seizures as well as stroke and dementia.33 Now, these effects have been validated by modern science.

In one clinical trial, gastrodin was found to reduce the total number and the duration of migraine attacks—and was even more effective than the leading drug flunarizine.30 Other studies have also shown that gastrodin has a higher overall effective rate when compared to flunarizine.34-36

How it Works

Studies show that gastrodin-based formulas improve brain blood flow, which is commonly reduced during migraines.12,29 In fact, due to gastrodin’s powerful effect on blood flow, doctors in China use it to treat stroke victims, whose decrease in brain blood flow is life-threatening.37,38

But perhaps gastrodin’s most exciting mechanism of action stems from its ability to modulate both excitatory and inhibitory neurotransmitters: It raises GABA levels to normal by blocking the enzymes that break it down,11,27 and it decreases levels of excitatory neurotransmitters.28,39,40

Restoring this balance has been shown to be neuro-protective, even against the massive decrease in brain blood flow seen in strokes.28,33,39

Clearly, gastrodin’s multiple mechanisms of action make it an effective choice in the treatment and prevention of migraine headaches. But as we’re about to see, adding magnesium enhances the benefits of gastrodin for comprehensive migraine prevention.

Magnesium for Migraine Relief

Magnesium for Migraine Relief

Magnesium supplementation has been proven to be effective at preventing and reducing the duration of migraine headaches—with one dramatic study demonstrating a complete disappearance of pain in 87% of those given intravenous magnesium sulfate—and 100% of patients responding to treatment.41

And in another impressive study, 80% of patients receiving intravenous magnesium sulfate experienced complete pain relief within 15 minutes of the injection, along with complete elimination of hypersensitivity to light or sound.42

Doctors in hospitals and clinics have even started using intravenous magnesium sulfate to treat an existing migraine headache.41-44

Clinical trials have demonstrated the benefits of oral magnesium as well. One study found that 360 mg of magnesium reduced the number of days women experienced headaches during their menstrual cycles,45 a study of both male and female migraine patients found that 600 mg/day of magnesium in the form of trimagnesium dicitrate significantly reduced the incidence of migraine headaches,46 and another study found that magnesium supplementation reduced the irritation of facial and neck muscles that is common in migraines.47

In total, more than a half a dozen solid clinical trials have now demonstrated the utility of oral magnesium for preventing migraines and reducing their severity.45-51

How it Works

Magnesium for Migraine Relief  

Magnesium is increasingly being recommended for migraine prevention—and for good reason.13,50,51 When it comes to treating and preventing migraines, the mineral magnesium is able to work hand-in-hand with gastrodin to improve brain blood flow and to help balance the brain’s neurotransmitters.

Studies show that up to 50% of migraine patients are deficient in magnesium during an attack, and that they have a high ratio of calcium to magnesium.13,52 This imbalance sets the stage for the contraction of brain blood vessels resulting in a reduction of blood flow.52

Researchers using high-tech Doppler ultrasound to measure blood flow velocity in a major brain artery have definitively proven that supplementation with magnesium does increase both brain blood flow and its velocity.48,53

Like gastrodin, magnesium also has beneficial effects on the balance of excitatory to inhibitory neurotransmitters. Magnesium is a natural blocker of the excitatory receptor on brain cells, so when ample magnesium is available those receptors don’t trigger the excitatory electrical impulse.54-56 This allows the brain to move into its more balanced, calm mode.

Summary

Despite the fact that migraine headaches affect around 18% of American women and 6% of men, mainstream medicine has yet to find a safe, long-term way to prevent this debilitating condition.1

Two natural substances have now been found to be effective in preventing and often in treating migraine headaches. Together, gastrodin and magnesium target the underlying mechanisms of migraines, improving brain blood flow and restoring balance to the brain chemicals neurotransmitters.11-13,27-32

By calming the brain and reducing its dangerous level of excitotoxicity, gastrodin and magnesium have been shown to minimize or eliminate migraine headaches.11,27,28,30,39,40,54-56 This is especially important as we learn how much migraines have in common with debilitating disorders such as strokes and dementia—and how greatly migraines raise your risk for those conditions.2,17,18

If you have any questions on the scientific content of this article, please call a Life Extension® Health Advisor at 1-866-864-3027.

References

  1. Available at: http://www.migraineresearchfoundation.org/fact-sheet.html. Accessed August 20, 2013.
  2. Sas K, Pardutz A, Toldi J, Vecsei L. Dementia, stroke and migraine—some common pathological mechanisms. J Neurol Sci. 2010 Dec 15;299(1-2):55-65.
  3. Rogawski MA. Common pathophysiologic mechanisms in migraine and epilepsy. Arch Neurol. 2008 Jun;65(6):709-14.
  4. Eggers AE. New neural theory of migraine. Med Hypotheses. 2001 Mar;56(3):360-3.
  5. Paemeleire K. Brain lesions and cerebral functional impairment in migraine patients. J Neurol Sci. 2009 Aug 15;283(1-2):134-6.
  6. Vlak MH, Rinkel GJ, Greebe P, Algra A. Risk of rupture of an intracranial aneurysm based on patient characteristics: a case-control study. Stroke. 2013 May;44(5):1256-9.
  7. Kanner AM. Are antiepileptic drugs used in the treatment of migraine associated with an increased risk of suicidality? Curr Pain Headache Rep. 2011 Jun;15(3):164-9.
  8. Landmark CJ. Targets for antiepileptic drugs in the synapse. Med Sci Monit. 2007 Jan;13(1):RA1-7.
  9. Reynolds MF, Sisk EC, Rasgon NL. Valproate and neuroendocrine changes in relation to women treated for epilepsy and bipolar disorder: a review. Curr Med Chem. 2007;14(26):2799-812.
  10. Bie X, Chen Y, Han J, Dai H, Wan H, Zhao T. Effects of gastrodin on amino acids after cerebral ischemia-reperfusion injury in rat striatum. Asia Pac J Clin Nutr. 2007;16 Suppl 1:305-8.
  11. An SJ, Park SK, Hwang IK, et al. Gastrodin decreases immunoreactivities of gamma-aminobutyric acid shunt enzymes in the hippocampus of seizure-sensitive gerbils. J Neurosci Res. 2003 Feb 15;71(4):534-43.
  12. Jingyi W, Yasuhiro M, Naoya H, et al. Observation on the effects of Chinese medicine zhenxuanyin for improving cerebral blood flow in rats with cerebral ischemia. J Tradit Chin Med. 1997 Dec;17(4):299-303.
  13. Mauskop A, Varughese J. Why all migraine patients should be treated with magnesium. J Neural Transm. 2012 May;119(5):575-9.
  14. Talebi M, Savadi-Oskouei D, Farhoudi M, et al. Relation between serum magnesium level and migraine attacks. Neurosciences (Riyadh). 2011 Oct;16(4):320-3.
  15. Aradi M, Schwarcz A, Perlaki G, et al. Quantitative MRI studies of chronic brain white matter hyperintensities in migraine patients. Headache. 2013 May;53(5):752-63.
  16. Debette S, Beiser A, DeCarli C, et al. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. Stroke. 2010 Apr;41(4):600-6.
  17. Kuo CY, Yen MF, Chen LS, et al. Increased risk of hemorrhagic stroke in patients with migraine: a population-based cohort study. PLoS One. 2013;8(1):e55253.
  18. Chuang CS, Lin CL, Lin MC, Sung FC, Kao CH. Migraine and risk of dementia: A nationwide retrospective cohort study. Neuroepidemiology. 2013 Jul 30;41(3-4):139-145.
  19. Meguro K, Akanuma K, Ouchi Y, Meguro M, Nakamura K, Yamaguchi S. Vascular dementia with left thalamic infarction: neuropsychological and behavioral implications suggested by involvement of the thalamic nucleus and the remote effect on cerebral cortex. The Osaki-Tajiri project. Psychiatry Res. 2013 Jul 30;213(1):56-62.
  20. Available at: http://www.ninds.nih.gov/disorders/stroke/preventing_stroke.htm. Accessed August 28, 2013.
  21. Lauritzen M. Cerebral blood flow in migraine and cortical spreading depression. Acta Neurol Scand Suppl. 1987;113:1-40.
  22. Olsen TS, Friberg L, Lassen NA. Migraine aura--vascular or neuronal disease? Ugeskr Laeger. 1990 May 21;152(21):1507-9.
  23. Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol. 1981 Apr;9(4):344-52.
  24. Gonzalez de la Aleja J, Ramos A, Mato-Abad V, et al. Higher glutamate to glutamine ratios in occipital regions in women with migraine during the interictal state. Headache. 2013 Feb;53(2):365-75.
  25. Longoni M, Ferrarese C. Inflammation and excitotoxicity: role in migraine pathogenesis. Neurol Sci. 2006 May;27 Suppl 2:S107-10.
  26. Plummer PN, Colson NJ, Lewohl JM, et al. Significant differences in gene expression of GABA receptors in peripheral blood leukocytes of migraineurs. Gene. 2011 Dec 15;490(1-2):32-6.
  27. Liu W, Su BL, Wang ZS, Zhang X, Gao YS, Song SW. Gastrodin improved baroreflex sensitivity and increased gamma-amino butyric acid content in brains without decreasing blood pressure in spontaneously hypertensive rats. CNS Neurosci Ther. 2012 Oct;18(10):873-5.
  28. Zeng X, Zhang S, Zhang L, Zhang K, Zheng X. A study of the neuroprotective effect of the phenolic glucoside gastrodin during cerebral ischemia in vivo and in vitro. Planta Med. 2006 Dec;72(15):1359-65.
  29. Lu SL, Liu X, Wang JL, et al. The development of nao li shen and its clinical application. J Pharm Pharmacol. 1997 Nov;49(11):1162-4.
  30. Guo X, Nie Y. Short-term therapeutic efficacy of gastrodin on migraine. Chinese Journal of General Practice. 2011;9(4).
  31. Morris ME. Brain and CSF magnesium concentrations during magnesium deficit in animals and humans: neurological symptoms. Magnes Res. 1992 Dec;5(4):303-13.
  32. Mauskop A, Altura BT, Cracco RQ, Altura BM. Deficiency in serum ionized magnesium but not total magnesium in patients with migraines. Possible role of ICa2+/IMg2+ ratio. Headache. 1993 Mar;33(3):135-8.
  33. Kumar H, Kim IS, More SV, Kim BW, Bahk YY, Choi DK. Gastrodin protects apoptotic dopaminergic neurons in a toxin-induced Parkinson’s disease model. Evid Based Complement Alternat Med. 2013;2013:514095
  34. Youlai Z. Therapeutic efficacy of gastrodin on migraine. The Medical Forum. 2006;10(4).
  35. Guo F. Aerospace Medicine. 2009 September.
  36. Bai Y, Zhao Y. Controlled clinical trial of gastrodine combined with flunarizine in prevention of migraine attack. Journal of Mudanjiang Medical University. 2009;30(1).
  37. Li H, Fan P, Li K, Jiang J, PeI R. Effect of Naloxone combined with Gastrodin in treatment of actue cerebral infarction. China Modern Doctor. 2012:122-25.
  38. Wei J-j, Zhou Y-l. Treatment of posterior circulation ischemia with gastrodin and betahistine. Practical Clinical Medicine. 2012;13(4).
  39. Xu X, Lu Y, Bie X. Protective effects of gastrodin on hypoxia-induced toxicity in primary cultures of rat cortical neurons. Planta Med. 2007 Jun;73(7):650-4.
  40. Zeng X, Zhang Y, Zhang S, Zheng X. A microdialysis study of effects of gastrodin on neurochemical changes in the ischemic/reperfused rat cerebral hippocampus. Biol Pharm Bull. 2007 Apr;30(4):801-4.
  41. Demirkaya S, Vural O, Dora B, Topcuoglu MA. Efficacy of intravenous magnesium sulfate in the treatment of acute migraine attacks. Headache. 2001 Feb;41(2):171-7.
  42. Mauskop A, Altura BT, Cracco RQ, Altura BM. Intravenous magnesium sulfate rapidly alleviates headaches of various types. Headache. 1996 Mar;36(3):154-60.
  43. Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study. Cephalalgia. 2002 Jun;22(5):345-53.
  44. Cete Y, Dora B, Ertan C, Ozdemir C, Oktay C. A randomized prospective placebo-controlled study of intravenous magnesium sulphate vs. metoclopramide in the management of acute migraine attacks in the Emergency Department. Cephalalgia. 2005 Mar;25(3):199-204.
  45. Facchinetti F, Sances G, Borella P, Genazzani AR, Nappi G. Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache. 1991 May;31(5):298-301.
  46. Taubert K. Magnesium in migraine. Results of a multicenter pilot study. Fortschr Med. 1994 Aug 30;112(24):328-30.
  47. Thomas J, Tomb E, Thomas E, Faure G. Migraine treatment by oral magnesium intake and correction of the irritation of buccofacial and cervical muscles as a side effect of mandibular imbalance. Magnes Res. 1994 Jun;7(2):123-7.
  48. Koseoglu E, Talaslioglu A, Gonul AS, Kula M. The effects of magnesium prophylaxis in migraine without aura. Magnes Res. 2008 Jun;21(2):101-8.
  49. Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia. 1996 Jun;16(4):257-63.
  50. Tarighat Esfanjani A, Mahdavi R, Ebrahimi Mameghani M, Talebi M, Nikniaz Z, Safaiyan A. The effects of magnesium, L-carnitine, and concurrent magnesium-L-carnitine supplementation in migraine prophylaxis. Biol Trace Elem Res. 2012 Dec;150(1-3):42-8.
  51. Wang F, Van Den Eeden SK, Ackerson LM, Salk SE, Reince RH, Elin RJ. Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Headache. 2003 Jun;43(6):601-10.
  52. Mauskop A, Altura BT, Cracco RQ, Altura BM. Deficiency in serum ionized magnesium but not total magnesium in patients with migraines. Possible role of ICa2+/IMg2+ ratio. Headache. 1993 Mar;33(3):135-8.
  53. Lysakowski C, Von Elm E, Dumont L, et al. Effect of magnesium, high altitude and acute mountain sickness on blood flow velocity in the middle cerebral artery. Clin Sci (Lond). 2004 Mar;106(3):279-85.
  54. Safar MM, Abdallah DM, Arafa NM, Abdel-Aziz MT. Magnesium supplementation enhances the anticonvulsant potential of valproate in pentylenetetrazol-treated rats. Brain Res. 2010 Jun 2;1334:58-64.
  55. Lyden P, Wahlgren NG. Mechanisms of action of neuroprotectants in stroke. J Stroke Cerebrovasc Dis. 2000 Nov;9(6 Pt 2):9-14.
  56. Afshari D, Moradian N, Rezaei M. Evaluation of the intravenous magnesium sulfate effect in clinical improvement of patients with acute ischemic stroke. Clin Neurol Neurosurg. 2013 Apr;115(4):400-4.